Literature DB >> 6096898

A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?

F Boismare, M Daoust, N Moore, C Saligaut, J P Lhuintre, P Chretien, J Durlach.   

Abstract

The effects of some derivatives of homotaurine (3 APS), the well known GABA agonist, were tested on the voluntary intake of ethanol by rats. Spontaneously ethanol drinking rats (DR) were selected and had a constant voluntary intake of ethanol by rats. Spontaneously ethanol drinking rats (DR) were selected and had a constant voluntary intake of a 12% ethanol solution (VIE) during 14 days (about 5 g/kg body weight daily). Calcium acetylhomotaurine (0.26 and 0.52 mmol/kg daily IP) significantly reduced VIE and this was inhibited by the GABA antagonist bicuculline (2 mg/kg IP). The conditioned aversion test to saccharin was negative. Bicuculline alone did not affect VIE. Other homotaurine (3-APS) derivatives: sodium acetyl homotaurine (Na AOTA), homotaurine (OTA), sodium acetyltaurine (Na A TA) and calcium chloride (CaCl2) did not affect VIE. These data suggest that the gabaergic system could be implicated in VIE. MERAM Lab. patent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6096898     DOI: 10.1016/s0091-3057(84)80020-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  30 in total

Review 1.  Rational development of addiction pharmacotherapies: successes, failures, and prospects.

Authors:  R Christopher Pierce; Charles P O'Brien; Paul J Kenny; Louk J M J Vanderschuren
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Reply to: Does acamprosate really produce its anti-relapse effects via calcium? No support from the PREDICT study in human alcoholics.

Authors:  Rainer Spanagel; Valentina Vengeliene; Falk Kiefer
Journal:  Neuropsychopharmacology       Date:  2016-02       Impact factor: 7.853

Review 3.  Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.

Authors:  Philippe De Witte; John Littleton; Philippe Parot; George Koob
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Role of altered structure and function of NMDA receptors in development of alcohol dependence.

Authors:  József Nagy; Sándor Kolok; András Boros; Péter Dezso
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 5.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

Review 6.  The development of acamprosate as a treatment against alcohol relapse.

Authors:  Peter R Kufahl; Lucas R Watterson; M Foster Olive
Journal:  Expert Opin Drug Discov       Date:  2014-09-26       Impact factor: 6.098

Review 7.  Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

Authors:  M I Wilde; A J Wagstaff
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

8.  Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.

Authors:  Mary W Hulin; Michelle N Lawrence; Russell J Amato; Peter F Weed; Peter J Winsauer
Journal:  Alcohol       Date:  2015-01-06       Impact factor: 2.405

Review 9.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 10.  Clinical pharmacokinetics of acamprosate.

Authors:  S Saivin; T Hulot; S Chabac; A Potgieter; P Durbin; G Houin
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.